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ABSTRACT
The ESMO Magnitude of Clinical Benefit Scale
(ESMO-MCBS) is a standardised, generic, validated tool
to stratify the magnitude of clinical benefit that can be
anticipated from anticancer therapies. The ESMO-MCBS
is intended to both assist oncologists in explaining the
likely benefits of a particular treatment to their patients
as well as to aid public health decision makers’ prioritise
therapies for reimbursement. From its inception the
ESMO-MCBS Working Group has invited questions and
critiques to promote understanding and to address
misunderstandings regarding the nuanced use of the
scale, and to identify shortcomings in the scale to be
addressed in future planned revisions and updates. The
ESMO-MCBS V.1.0 has attracted many questions
regarding its development, structure and potential
applications. These questions, together with responses
from the ESMO-MCBS Working Group, have been edited
and collated, and are herein presented as a
supplementary resource.
INTRODUCTION
The ESMO Magnitude of Clinical Beneﬁt
Scale (ESMO-MCBS) is a standardised,
generic, validated tool to stratify the magni-
tude of clinical beneﬁt that can be antici-
pated from anticancer therapies. The
ESMO-MCBS is intended to both assist oncol-
ogists in explaining the likely beneﬁts of a
particular treatment to their patients as well
as to help decision makers prioritise out-
standing new drugs for reimbursement.
SCALE DEVELOPMENT
Which payers/reimbursement agencies were
consulted on the use of this tool? How does
ESMO envisage payers using the
ESMO-MCBS?
Answer
▸ The scale has not been discussed with any
payer organisations.
▸ The scale was developed as a tool to
derive clear and unbiased evaluation of
the magnitude of clinical beneﬁt based
on published peer-reviewed data.
▸ When governments are the payer, as is
common in many European countries, we
envisage that the ESMO-MCBS will assist
in the Health Technology Assessment
process. This is described in our paper1
where we write: “Grading derived from
the ESMO-MCBS provides a backbone for
value evaluations for cancer medicines.
Medicines and therapies that fall into the
ESMO-MCBS A+B for curative therapies
and 4+5 for non-curative therapies should
be highlighted for accelerated assessment
of value and cost-effectiveness. While a
high ESMO-MCBS score does not auto-
matically imply high value (that depends
on the price), the scale can be used to
frame such considerations and can help
public policymakers advance ‘accountabil-
ity for reasonableness’ in resource alloca-
tion deliberations.”
SCALE STRUCTURE AND CRITERIA
Will ESMO consider taking proportional
benefit (ie, a percentage gain relative to
current survival in orphan or difficult-to-treat
cancers) into account beyond focusing on
absolute overall survival (OS)/progression-free
survival (PFS)? If proportionality were to be
taken into account, then the percentage gain
of OS for a drug in a rare or difficult-to-treat
cancer would have quite a different benefit
rating. Equally some of the cancers for which
survival is already very good might have their
rankings changed.
Answer
▸ All of the quantitative elements of the
scale, both for PFS and OS, take into
account both absolute gain and hazard
ratio (HR). HR data takes proportionality
into account.
▸ The scale is stratiﬁed for diseases with
better and worse prognosis, that is, there
is a different scoring of PFS for disease
with PFS in the control arm >6 months or
<6 months, and for median OS
>12 months or <12 months.
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If the ESMO-MCBS is only to be applied to comparative
studies, what will that mean for breakthrough therapies,
licenced on single arm data?
Answer
▸ The grading of single arm data will be incorporated
into version 1.1 of the ESMO-MCBS.
Evaluation form 1—for new approaches to adjuvant
therapy or new potentially curative therapies grade A (for
grade B and C analogously): What is the specific meaning
of ‘in studies without mature survival data’? Assuming we
have survival data at 3 years but the improvement is 4%.
At the same time, we have an improvement in disease-
free survival (DFS) of HR=0.60. What would then be the
correct grading? Grade A (both conditions connected by
OR) or grade B (condition on DFS only matters if 3 years
survival data are missing)?
Answer
▸ In general, once mature survival data becomes avail-
able, the DFS, which is a surrogate indicator of sur-
vival, becomes redundant and in the example given
here the ESMO-MCBS score would be B.
▸ However, in rare instances in which DFS was the
primary outcome and where there was major cross-
over because of early analysis leading to an unblind-
ing of the randomisation (as happened in some of
the trastuzumab trials) the DFS scoring would prevail.
How is the statistical significance of effects incorporated
in your method? Since it is not explicitly mentioned in the
text of the article, can we assume that a statistically
significant result (ie, p value <0.05) for a primary end
point is a general requirement for a positive grading?
Answer
▸ YES. In the section ‘eligibility for application of the
ESMO-MCBS’ the article1 is very speciﬁc: ‘The
ESMO-MCBS can be applied to comparative outcome
studies evaluating the relative beneﬁt of treatments
using outcomes of survival, quality of life (QoL), sur-
rogate outcomes for survival or QoL (disease-free
interval, event-free survival (EFS), time to recurrence,
PFS and time to progression) or treatment toxicity in
solid cancers. Eligible studies can have either a rando-
mised or comparative cohort design or a
meta-analysis which report statistically signiﬁcant
beneﬁt from any one or more of the evaluated
outcomes’.
Can you advise if there is any upgrading of the
ESMO-MCBS if QoL is evaluated as a secondary outcome
(eg, first question listed below is marked)? Or is there
only an upgrading of 1 point if QoL is improved or there is
less toxicity (eg, only if second or third question listed
below is marked)?
Answer
▸ YES. Upgrading for improved QoL is incorporated in
to the evaluation of both OS studies (form 2a) and
PFS studies (form 2b illustrated below)
QoL/grade 3–4 toxicities assessment
Mark with X
if relevant
Was quality of life (QoL) evaluated as
secondary outcome?
Does secondary end point QoL show
improvement
Are there statistically significantly less
grade 3–4 toxicities impacting on daily
well-being*
*This does not include alopecia and myelosuppression, but rather
chronic nausea, diarrhoea, fatigue, etc.
Adjustments
A. Downgrade 1 level if there is one or more of the
above incremental toxicities associated with the new
drug
B. Upgrade 1 level if improved QoL or if less grade 3–4
toxicities that bother patients are demonstrated
C. When OS as secondary end point shows improve-
ment, it will prevail and the new scoring will be
carried out according to form 2a
D. Downgrade 1 level if the drug ONLY leads to
improved PFS and QOL assessment does not demon-
strate improved QoL
Final, toxicity and QoL adjusted, magnitude clinical
beneﬁt grade
4 3 2 1
Highest magnitude clinic benefit grade that can be achieved
grade 4.
▸ In PFS studies in which QoL is evaluated, a positive
outcome demonstrating either improved QoL or
delayed deterioration in QoL provides further sup-
portive evidence regarding the signiﬁcance of the
PFS advantage reported.
– If improved QoL OR delayed deterioration in QoL
is observed in QoL evaluation (statistically signiﬁ-
cant), then the score can be upgraded by 1 point.
– If however, PFS improvement is not accompanied
by OS advantage and evaluation of QoL does not
conﬁrm that QoL was either improved or deterior-
ation is delayed, this essentially devalues the PFS
and scores are reduced by 1 point.
▸ In our ﬁeld testing there were many instances of scores
being upgraded to 4 based on both high PFS score and
improved QoL. There were three instances where PFS
scores were downgraded because PFS was not associated
with either statistically signiﬁcant improvement in OS or
a signiﬁcant positive effect on QoL.
▸ The rationale for this approach is that PFS is, in
general, an unreliable surrogate for both OS and
QoL improvement, and secondary outcomes can
either lend veracity to the ﬁndings or indicate that
they are of lesser clinical signiﬁcance to patient
outcomes.
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You are describing for forms 2a and 2b that OS is graded
based on the lower limit of the 95% CI of the effect. There is
no specification how exactly the gain (in median survival) or
the increase in survivors is graded. Is it correct to assume
that you suggest using the point estimate of the effect
(rather than any limit of a CI)? Which measures should be
used in form 1 limits of CIs or point estimates?
Answer
▸ In forms 2a and 2b, HR is evaluated based on the lower
limit of the 95% CI. The median survival of the control
arm and the gain in median survival (for both PFS and
OS) are calculated based on point estimates.
▸ In form 1, the HR for DFS is evaluated based on the
lower limit of the 95% CI. The difference in 3 (or
more) year survival, the δ between the curves, is based
on point estimates and must be statistically signiﬁcant.
There is also currently an anomaly that if no health-related
quality of life (HRQoL) data is collected this element cannot
be scored, but this alone could drive differentiation between
therapies. This is the situation for studies of bevacizumab in
platinum-sensitive relapsed ovarian cancer which did not
collect HRQoL data. I would suggest that the scale should
deduct if there is a HRQoL detriment, add to the score if
there is HRQoL improvement and make no change if there is
no difference.
Answer
▸ PFS studies are in some ways the low hanging fruit of
registration outcomes and since PFS is such a weak
surrogate for survival or QoL it can be upgraded if
beneﬁt is supported by secondary outcomes such as
OS or QoL advantage. Many studies in other diseases
(often without OS advantage because of crossover at
progression) demonstrated improved QoL or delayed
deterioration in QoL, thus qualifying them for a high
score of 4. Studies are only penalised if secondary
data failed to show OS advantage AND conﬁrmed
that there was no QoL advantage.
▸ Studies that do not evaluate QoL, particularly those
with crossover, cannot be upgraded to a high
ESMO-MCBS score; this is why it is in the interest of
industry sponsors and researchers to evaluate QoL.
The risk in this, however, is that sometimes a lack of
QoL advantage is conﬁrmed and this actually lowers
the value of the PFS score. Be aware that this
occurred with olaparib and with bevacizumab and
everolimus in breast cancer which similarly have
strong PFS data but no OS or QoL advantage.
The ESMO-MCBS currently cannot contextualise other
aspects potentially relevant to healthcare
decision-making, such as the level of unmet clinical
need, the maturity of data and the level of confounding of
overall survival which are increasingly relevant in
oncology with accelerated approvals.
Answer
▸ ESMO-MCBS data is unrelated to licencing approvals;
as described in the article,1 it is a tool to assist in the
processes of Health Technology Assessment (HTA)
(which takes into consideration unmet needs etc).
The tool is stratiﬁed for prognosis and this is one of
its strengths. Finally, when mature data evolves and is
published in peer-reviewed papers it can generate an
upgrading. This was also commonly observed, particu-
larly in melanoma and colorectal cancer studies (also
described in the article).
The scale does not consider the heterogeneity of patient
populations, but instead assumes all patients would have
similar benefits from the treatments.
Answer
▸ For all treatments there will be some patients who will
be outstandingly unresponsive and, at the other
extreme, there will be exceptional responders. To
some degree, the ESMO-MCBS addresses this by
looking at not only median survival data but also late
survival data (in situations when mature data is avail-
able). Thus, for diseases with a control median sur-
vival of less than 12 months, the scale evaluates and
credits survival advantage at 2 years, and for diseases
with control median survival of more than 12 months
3-year survival advantage is credited.
With this grading, treatments that are meant for patients
with refractory disease or those with a poor prognosis are
inherently disadvantaged?
Answer
▸ One of the strengths of the ESMO-MCBS is its prog-
nostic stratiﬁcation. In the design of this tool we have
gone to great lengths to give recognition to improve-
ments in outcomes for both poor prognostic diseases,
which are diseases that have an OS of <12 months in
the control arm, or median PFS of <6 months in the
control arm. Thus, smaller absolute gains in either
PFS or OS can achieve the same scale of scoring in
poor prognostic diseases as a greater gain seen in
better prognostic situations.
Using an active versus placebo comparator was not
accounted for, especially within the prostate cancer
scores.
Answer
▸ The Helsinki requirements of the World Medical
Association for Ethical Human Research require that
the control arm be ‘best evidence supported prac-
tice’.2 This is essentially limited to the situation in
which there is no evidence-based standard for
ongoing disease modifying care. Thus, in all situa-
tions where there is an evidence-based standard for
ongoing care this must be incorporated as a control
arm.
▸ With regard to castration-resistant prostate cancer,
particularly after the failure of docetaxel chemother-
apy, both options of either prednisone alone or pred-
nisone in combination with mitoxantrone have been
incorporated as control arms in different studies.3
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Given that the studies comparing mitoxantrone/pred-
nisolone versus prednisolone alone showed no sur-
vival advantage both have been accepted as
reasonable control arms. It is, however, arguable that
mitoxantrone/prednisone should be the appropriate
control arm since there is some, albeit relatively soft,
evidence that this combination improves patient-
reported subjective outcomes, although this view is
not universally held.
The stratification based on the control arm outcomes is
binary and somewhat arbitrary. This stratification of the
OS and PFS could result in different grades for therapies
and can be misleading about the outcomes.
Answer
▸ Part of the challenge in developing the scale has
been to introduce a clear and simple approach to
grading, but which incorporates enough nuance to
be able to fairly represent studies in different prog-
nostic settings and using different outcome measures.
▸ The prognostic cut-off points were derived based on
the input of multiple expert clinicians as well as
detailed statistical review. Based on our experience in
ﬁeld testing that was published1 and reviewed by
experts in each of the different disciplines (including
prostate cancer) the feedback was that these cut-off
points were fair and reasonable. However, this will be
one of the subjects which will be reviewed in our
ongoing deliberations regarding the development of
the ESMO-MCBS.
Adding a sentence indicating that a small magnitude of
clinical benefit may be of great importance in some types
of tumours with less therapeutic options and could help to
highlight that there are differences across tumour types
when interpreting the results of this ESMO-MCBS.
Answer
▸ The Annals of Oncology article published in 20151 is
predicated on the commitment to promote profes-
sional integrity in discussing anticipated outcomes
and treatment options. This commitment would
suggest that when the likelihood of beneﬁt or the
quantity of expected beneﬁt is small this ought to be
explained to patients (with care and sensitivity) as
part of the process of informed decision-making.
▸ In situations where there is no treatment with a high
ESMO-MCBS we would advise clinicians to counsel
patients explaining that there are some treatments
that may provide beneﬁt to them, but that on average
the likelihood or the amount of beneﬁt may be
limited. This discussion should also address best and
worst case outcomes and the options to either con-
sider participating in research (if a relevant trial is
available) or to receive supportive and palliative care
without anticancer treatment which may be quite rea-
sonable in this setting.
When reviewing the colorectal and ovarian tables, I
wonder if phase II trials, which are essentially
exploratory, without a prespecified statistical hypothesis
should be removed completely from these tables.
Answer
▸ As discussed in the Annals of Oncology article,1 we
carefully researched the issue of randomised phase
II papers. Our conclusion to include them is sup-
ported and referenced by a major review of the val-
idity of this genre of study by a cohort of leading
cancer biostatisticians which concluded “Although
each side of this debate has forcefully presented the
favourable attributes of their nominated trial design,
all the authors acknowledge that efﬁcient drug
development will require the appropriate use both
SA-II and RP-II trials. Table 4 in the Annals of
Oncology article1 provides some guidelines regard-
ing scenarios that the authors unanimously agree
would favour the use of one particular trial design.
SA-II trials may be preferred for single agents with
tumour response end points—especially in rare
tumours whereas RP-II may be preferred for trials of
combination therapy and/or with time to event end
points. The key requirement before considering an
RP-II trial is a determination that completion of
such a trial is feasible. Clearly, more research is
required to compare efﬁcacy of SA-II and RP-II
trials, as well as to develop more adaptive/effective
phase II designs.”4
It is too strong to say that panitumumab in the PEAK trial
(phase II random) has an ESMO-MCBS scoring of 4.
Answer
▸ We share concerns about the ﬁndings of the PEAK
study5 and these concerns are addressed in the
article1 where we emphasise that the interpretation
of the ESMO-MCBS must take into account factors
that may have either artiﬁcially inﬂated the score,
such as unbalanced crossover. For this reason, the
score is asterisked in the table and there is a
detailed discussion in the text: Unbalanced crossover:
“In other instances, unbalanced crossover may exag-
gerate differences in survival. For instance, in the
PEAK study comparing FOLFOX6 with either beva-
cizumab or panitumumab among the patients with
KRAS wild-type tumours, only 38% of those in the
bevacizumab arm received any epidermal growth
factor receptor (EGFR) antibody in subsequent
therapy. Although this study showed a survival
advantage of 9.9 months over a baseline of
24.3 months for patients initiated on treatment with
panitumumab, it remains unclear as to whether this
was affected by the sequence of treatments or if it
resulted from the fact that more than half of the
patients in the bevacizumab arm were never
exposed to an EGFR antibody.”
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The magnitude of benefit is considered the same
regardless of the type of cancer. However, we all know
that the available therapies that exist for a given
malignancy also influence the magnitude of benefit we
are able to accept as high enough.
Answer
▸ In developing the ESMO-MCBS V.1.0 we recognised
that different conditions have different prognoses
and that this is inﬂuenced by the nature of the
disease and stage and also by best available therapies.
▸ We believe that the concern raised here is addressed
by the stratiﬁcation of the beneﬁt scales for non-
curable disease by prognosis. The scoring thresholds
are different with median survival in controls of less
than or more than a year and the thresholds for PFS
scoring similarly differ for PFS in controls <6 months
and >6 months. We believe that the robustness of this
approach across a wide range of conditions is well
demonstrated in the ﬁeld testing results.
There is no discussion about pathologic complete
response (pCR). I understand this is only relevant for
some types of cancer but it would be important to state if
the scale considers pCR as a response-rate-like end point
and if it does or does not assess phase 3 trials that have
used this end point (and there are many). For example,
no drug is evaluated based on pCR in the breast cancer
field and we are now facing an era where some drugs are
being approved based on pCR data only (eg, pertuzumab
by the Food and Drug Administration (FDA) and currently
undergoing evaluation by the European Medicines Agency
(EMA)).
Answer
▸ We had substantial internal discussions within the
group regarding pCR as a surrogate outcome for
curative therapies.
This is a point of contention and we appreciate that
the level of evidence may change.
At this time the membership of the ESMO-MCBS
working group does not feel that there is adequate
evidence of the robustness of pCR as a reliable surro-
gate for inclusion in the scale. While recognising
that this decision will be debated, and may be subject
to future amendments, we felt that it was the best
decision based on consideration of the currently
available best evidence.
This was the conclusion of two recent meta-analyses:
1. The conclusion from the study by Berruti et al6 was
“This meta-regression analysis of 29 heterogeneous
neoadjuvant trials does not support the use of pCR
as a surrogate end point for DFS and OS in patients
with breast cancer. However, pCR may potentially
meet the criteria of surrogacy with speciﬁc systemic
therapies.”
2. Cortazar et al7 concluded: “Our pooled analysis could
not validate pathological complete response as a sur-
rogate end point for improved EFS and OS.”
This remains an active issue of research and the state
of the science will be reviewed when considering
future revisions.
It is not clear when we read the article1 why certain types
of studies were grouped under the form 2c.
Are these considered of less quality? Why are
non-inferiority trials (which are good if well designed) and
trials with response rate (RR) as an end point grouped
together? Why is QoL also under this group? I am not
saying it is not possible but it needs further explanation.
Answer
▸ Evidence of clinical beneﬁt is mainly derived from
comparative studies in which the primary outcome is
either improved OS (or its surrogate DFS), OS or its
surrogate PFS.
Three groups of studies which are outliers include:
1. Non-inferiority studies: those which aim to demon-
strate non-inferior primary outcomes, with important
secondary outcomes of improved toxicity, QoL or
cost. While this tool does not address cost, non-
inferiority with improved toxicity or QoL is scored
very highly.
2. QoL studies: there was only a single study (of early
palliative care in metastatic lung cancer) in which
this was the primary outcome.
3. RR: there were very few contemporary studies in
which this was the primary outcome. RR is a weak
surrogate for survival and even for QoL and conse-
quently this is a low level of evidence for beneﬁt.
APPLICATION, POLICY IMPLICATIONS AND FEEDBACK
Who will do the ESMO-MCBS assessment and how does
validation take place? How will industry, patient
advocates and others be able to provide feedback on
subsequent ratings given to new treatments?
Answer
▸ ESMO has established a portal for feedback on the
ESMO-MCBS from the oncology community.
▸ Feedback can be submitted to mcbs@esmo.org.
▸ The evaluation of newly approved EMA anti-cancer
medicines will be completed by the ESMO Guidlines
Committee.
▸ All feedback will be taken into consideration by the
ESMO-MCBS Working Group and ESMO Executive
Board.
Extrapolation from trial data to the general population is
an issue not for the ESMO-MCBS but when recommending
a specific drug. The target population of the trial is the
one in which a particular intervention is to be applied.
Answer
▸ We share this same concern and have addressed this
in the editorial “Proven efﬁcacy, equitable access and
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adjusted pricing of anticancer therapies: no ‘sweet-
heart’ solution” Tabernero.8
▸ Furthermore, in the section on validity of the
scale1 we write: “ESMO-MCBS scores for a speciﬁc
therapy are not generalisable to indications
outside the conﬁnes of the context in which they
have been evaluated. Consequently, the
ESMO-MCBS score for a particular medication or
therapeutic approach may vary depending on the
speciﬁcs of the indication and may vary between
studies”.
How will ESMO ensure their message around the
ESMO-MCBS scale is understood properly and
communicated accurately?
Answer
▸ The central aim of ESMO in developing the
ESMO-MCBS is to highlight those treatments
which provide major clinical beneﬁts in the hope
that they will be made available to the public as
fast as possible (pending HTA and value
assessments).
▸ ESMO also has a public commitment to present
‘clear and unbiased evaluations of the magnitude of
clinical beneﬁt’ as a matter of important public inter-
est and professional integrity.
▸ When the clinical beneﬁts derived from new treat-
ments are relatively limited, this is a matter of legitim-
ate public interest.
▸ Affordability of anticancer medication and value dis-
crepancy is of growing concern to ESMO (see the
editorial8), payers and the public and will inevitably
attract critical scrutiny.
Given that advances in the non-curative setting have often
been achieved with multiple incremental improvements,
how can we collaborate to ensure that innovators are able
to shoulder the inherent risk and not be de-incentivised to
tackle those more difficult-to-treat cancers?
Answer
▸ Incremental beneﬁts are, nonetheless, beneﬁts.
ESMO recognises that all EMA approved drugs
have demonstrated beneﬁts for patients, but it is
understanding the actual magnitude of the
beneﬁt that is often challenging and this is why
the development of a standardised grading scale
is useful.
▸ We hope that the emphasis on the importance of
innovations showing high levels of beneﬁt will
enhance the incentive to develop agents that substan-
tially improve health outcomes.
▸ The ESMO-MCBS assessment will be independently
made by ESMO experts.
▸ Feedback from industry or other parties can be made
through the ofﬁcial communication channel
mcbs@esmo.org.
As base assessments have been chosen to take place at
the pre-approval stage, how will ESMO manage the risk
that medicines will be evaluated prematurely before their
full value potential is studied and realised? Will scoring
fluctuate over time (eg, will high-scoring products receive
a lower score as more valuable innovations come to
market or will low-scoring products receive a higher score
as new information becomes available?) If so, how and
how often will these adjustments be made over time?
Answer
▸ ESMO will apply the scale to all drugs that have been
newly approved by the EMA. The pivotal published
clinical trials will be used for the grading assessment.
▸ Since some studies publish early data based on PFS
alone, we have seen and described in the article
examples where scores have been modiﬁed upward as
mature survival data emerged.1
▸ The ESMO-MCBS Working Group will be responsible
for an ongoing review of new product related data
after approval by the EMA. In the event that new data
in the same indication is published and the results
differ from the original grading, the grade allocated
will be modiﬁed accordingly, if appropriate.
In order to ensure that the ESMO-MCBS contributes to the
guiding principles which are solid ground for
policymaking, what are ESMO’s plans to make this
scientific assessment part of a larger discussion with all
relevant stakeholders to look into the overall value of what
an intervention, be it medicinal or other, can represent
and how it should then be placed in the system?
Answer
▸ ESMO would be very supportive of models of
pharmaceutical pricing that engaged professional
bodies and stakeholders based on the concept of a
negotiated ‘just price’.
▸ Such a process may incorporate models of either
‘value-based pricing’ or risk-sharing arrangements.
▸ ESMO supports pricing policies for anticancer medi-
cations that reﬂect the value of medications in terms
of healthcare beneﬁts, that are affordable and sustain-
able for healthcare systems, that are sensitive to the
needs and demands of developed economies, and to
those of emerging economies (possibly with differen-
tial pricing) and that deliver an adequate proﬁt to
maintain the incentive for research and development.
The methodology scores any one individual clinical trial
rather than the product overall. More recent evidence,
including real-world data is excluded; therefore, it is not
an accurate representation of the treatment experience.
Answer
▸ The ESMO-MCBS is a tool to grade the magnitude of
clinical beneﬁt observed from comparative clinical
studies. To date, randomised clinical studies have
proven to be the most reliable approach to evaluate
the relative merits of new agents as compared to the
control arm.
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As these scores reflect only a cross-section of the
available clinical data at the time of analysis, we would
like to ensure that the limitations are clearly conveyed
and the emerging evidence is appropriately incorporated.
Answer
▸ It is clearly indicated in the text that there is the
ongoing need to review subsequent publications and
update data where appropriate. Indeed, again as
described in the article,1 this did lead to upgrading
of scores for several therapeutic agents. In some
cases, scores were upgraded based on late published
survival data, in other cases scores were upgraded
when subgroups of patients (preplanned) were iden-
tiﬁed to have more substantial levels of beneﬁt. This
latter phenomenon was particularly prevalent for the
anti-EGFR agents in metastatic colorectal cancer.
▸ Furthermore, ESMO has appointed a Working Group
to re-evaluate agents and studies as further data
comes to hand and this will be made available to the
public. The format for this publication is currently
being developed.
CONCLUSION
The ESMO-MCBS will be a dynamic tool and its criteria
will be revised on a regular basis by a dedicated
ESMO-MCBS Working Group, taking into consideration
peer-reviewed feedback from other stakeholders and
developments in cancer research and therapies.
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